Blueprint
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of August 2017
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X
Form
40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __ No
X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule
12g3-2(b): 82-_____________
16 August 2017 07:00 BST
ASTRAZENECA NON-EXECUTIVE DIRECTOR RETIREMENT
AstraZeneca
announced that, on 31 August 2017, Bruce Burlington will retire as
a Non-Executive Director of AstraZeneca PLC and as a member of the
Audit Committee, the Nomination and Governance Committee, and from
his role as Chairman of the Science Committee.
Dr
Burlington joined the Board in 2010 and will have served for seven
years when he steps down.
Leif
Johansson, Chairman of AstraZeneca, said: "Bruce has been an
exemplary Director who has made a significant contribution to the
Board's work over many years. We have valued his insightful and
frank participation as a Board member, and Chairman of the Science
Committee during a period of innovation-led transformation at
AstraZeneca. His diligence and commitment to the work of the Audit
Committee and the Nomination and Governance Committee should also
be acknowledged. On behalf of all Board members, we will miss Bruce
as a colleague and send him our very best wishes for the
future."
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that
focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three main therapy areas - Oncology, Cardiovascular &
Metabolic
Diseases and Respiratory. The Company also is selectively active in
the areas of autoimmunity, neuroscience and infection. AstraZeneca
operates in over 100 countries and its innovative medicines are
used by millions of patients worldwide. For more information,
please visit www.astrazeneca.com_and
follow us on Twitter @AstraZeneca.
|
Media Relations
|
|
|
|
Esra
Erkal-Paler
|
UK/Global
|
+44 203 749 5638
|
|
Karen
Birmingham
|
UK/Global
|
+44 203 749 5634
|
|
Rob
Skelding
|
UK/Global
|
+44 203 749 5821
|
|
Matt
Kent
|
UK/Global
|
+44 203 749 5906
|
|
Jacob
Lund
|
Sweden
|
+46 8 553 260 20
|
|
Michele
Meixell
|
US
|
+1 302 885 2677
|
|
Investor Relations
|
|
|
|
Thomas
Kudsk Larsen
|
|
+44 203 749 5712
|
|
Craig
Marks
|
Finance, Fixed Income, M&A
|
+44 7881 615 764
|
|
Henry
Wheeler
|
Oncology
|
+44 203 749 5797
|
|
Mitchell
Chan
|
Oncology
|
+1 240
477 3771
|
|
Nick
Stone
|
Respiratory,
Brilinta
|
+44 203 749 5716
|
|
Christer
Gruvris
|
Diabetes; Autoimmunity, Neuroscience & Infection
|
+44 203 749 5711
|
|
US
toll free
|
|
+1 866
381 7277
|
Adrian Kemp
Company Secretary, AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
AstraZeneca
PLC
|
Date:
16 August 2017
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|